Susie Novis Durie News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Susie novis durie. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Susie Novis Durie Today - Breaking & Trending Today

International Myeloma Foundation (IMF) to Hold In-Person 2023 Patient and Family Seminar in Los Angeles in August

International Myeloma Foundation (IMF) to Hold In-Person 2023 Patient and Family Seminar in Los Angeles in August
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New York , United States , Los Angeles , Mount Elizabeth , Singapore General , Beverly Hills , Rafat Abonour , Briangm Durie , Sofitel Los Angeles , Sheri Baker , Yelak Biru , Boca Raton , Noopurs Raje , Susie Novis Durie , Donnad Catamero , Peter Anton , Roberta Vescio , Sinai Samuel Oschin Comprehensive Cancer Institute , Icahn School Of Medicine At Mount Sinai , Swan Research Initiative , International Myeloma Working Group , International Myeloma Foundation Patient , International Myeloma Foundation , Md University Of Indiana , Forum Discussion , Family Seminar ,

Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab

Date Time
Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab
NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE:PFE) today announced that the first participant has been dosed in the registration-enabling Phase 2 MagnetisMM-3 study (NCT04649359) of elranatamab (PF-06863135), an investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody, in patients with relapsed/refractory multiple myeloma. The study evaluates the efficacy and safety of elranatamab, administered subcutaneously, in patients with disease that is refractory to at least one agent in each of three major classes of medications approved for multiple myeloma. The study’s estimated primary completion date is June 2022. ....

United States , Alexanderm Lesokhin , Susie Novis Durie , Chris Boshoff , Pfizer Inc , International Myeloma Foundation , Drug Administration , Pfizer Global Product Development , Virtual American Society Of Hematology , Memorial Sloan Kettering Cancer Center , Fast Track Designation , Fast Track , Chief Development Officer , Pfizer Global Product , Virtual American Society , Annual Meeting , Memorial Sloan Kettering Cancer , International Myeloma , Immune Response , ஒன்றுபட்டது மாநிலங்களில் , ஃபைசர் இன்க் , சர்வதேச மைலோமா அடித்தளம் , ஃபைசர் உலகளாவிய ப்ராடக்ட் வளர்ச்சி , மெய்நிகர் அமெரிக்கன் சமூகம் ஆஃப் ஹீமாட்டாலஜி , நினைவகம் ஸ்லோன் கெட்டரிங் புற்றுநோய் மையம் , வேகமாக டிராக் பதவி ,